Lyophilized Drugs Market, by Drug Class (Anti-infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, and Others), by Indication (Infectious Disease, Autoimmune Disease, Gastrointestinal Disease, Cancer, and Others

Lyophilized Drugs Market, by Drug Class (Anti-infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, and Others), by Indication (Infectious Disease, Autoimmune Disease, Gastrointestinal Disease, Cancer, and Others), by Packaging Type (Vial, Injection, and Cartridge), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast, 2022 - 2028

Lyophilization or freeze drying is the process, in which the water content in the drug sample is frozen, followed by its removal from the sample. In the process of lyophilization, the frozen water content changes directly from solid to vapor without passing through a liquid phase. The process includes three steps: Freezing, primary drying (sublimation), and secondary drying (desorption). Pharmaceutical products that undergo lyophilization process include bulk pharmaceutical/biopharmaceutical ingredient (API), protein, collagen, peptide, oligonucleotide, enzymes, and mAbs.
Market Dynamics
Lyophilized drugs are majorly used to treat infectious diseases and autoimmune diseases. Thus, increasing prevalence of infectious diseases is expected to aid in growth of the global lyophilized drugs market. For instance, according to The Lancet Infectious Diseases (report) published in 2021, fungal infection affects over a billion people worldwide, resulting in around 11.5 million life-threatening infections and over 1.5 million deaths, annually. The number of lyophilized drugs such as Amphotericin B (Mycoflu), Vonfung NDD (voriconazole,) and other antifungal lyophilized drugs are available in market for treating fungal infections.
Lyophilized drug manufacturers are looking forward to expand their facilities to produce lyophilized drugs on large scale, which in turn contributing to growth of the global lyophilized drugs market. For instance, on January 2021, AB Technologies (AB) announced investment of US$ 10.5 million to build a new 23,000-square-foot manufacturing facility at its site in Bloomington, Indiana. The new facility will include manufacturing area for formulating, filling, lyophilizing, and packaging drugs for early-phase clinical trial studies. Moreover, AB Technologies (AB) added aseptic filling and lyophilizer loading systems into the new facility.
Major pharmaceutical manufacturers are engaged in the development and launching of innovative lyophilized drugs, which is expected to drive the global lyophilized drugs market growth. For instance, in November 2018, Xellia Pharmaceuticals launched Vancomycin Hydrochloride for Injection, USP within the U.S. market. Vancomycin Hydrochloride for Injection is lyophilized powder to treat or prevent infections that are caused by bacteria
Key features of the study:
This report provides in-depth analysis of the global lyophilized drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global lyophilized drugs market based on the following parameters – company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Sanofi S.A, Merck & Co., Inc., Fresenius Kabi USA, LLC., Ciron Drugs & Pharmaceuticals Pvt Ltd., GlaxoSmithKline plc., Mylan NV., Pfizer, Inc., Amneal Pharmaceuticals LLC, Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co., Ltd.), and BTG Plc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global lyophilized drugs market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global Lyophilized Drugs Market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Lyophilized Drugs Market, By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
Global Lyophilized Drugs Market, By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
Global Lyophilized Drugs Market, By Packaging Type:
Vial
Injection
Cartridge
Global Lyophilized Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
By Packaging Type:
Vial
Injection
Cartridge
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
By Packaging Type:
Vial
Injection
Cartridge
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
By Packaging Type:
Vial
Injection
Cartridge
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
By Packaging Type:
Vial
Injection
Cartridge
Middle East
By Country/Region:
GCC
Israel
Rest of Middle East
By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
By Packaging Type:
Vial
Injection
Cartridge
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Anti-infective
Antineoplastic
Diuretics
Proton Pump Inhibitor
Anesthetic
Anticoagulant
NSAID’s
Others
By Indication:
Infectious Disease
Autoimmune Disease
Gastrointestinal Disease
Cancer
Others
By Packaging Type:
Vial
Injection
Cartridge
Company Profiles
Sanofi S.A *
Company Overview
Technology Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co., Inc.
Fresenius Kabi USA, LLC.
Ciron Drugs & Pharmaceuticals Pvt Ltd.
GlaxoSmithKline plc.
Mylan NV.
Pfizer, Inc.
Amneal Pharmaceuticals LLC
Otsuka Holdings Co., Ltd. (Otsuka Pharmaceutical Co., Ltd.)
BTG Plc.
“*” marked represents similar segmentation in other categories in the respective section.